Targeting the Molecular Cause of Opioid Dependence

ATX-1209 is a first-in-class, oral, neutral μ-opioid receptor modulator designed to reduce opioid-induced physical dependence while preserving opioid analgesia.

The Opioid Crisis

A Public Health Emergency With No Adequate Treatment

The United States opioid crisis has claimed over 1 million lives since 1999 — and the problem of physical dependence remains largely unsolved for the millions of patients already receiving long-term opioid therapy for pain.[1]

44,500+
Opioid-related overdose deaths
in the U.S. in 2025 (provisional)[2]
5–8 Million
Americans on long-term
opioid therapy for chronic pain[3]
Nearly All
Chronic opioid therapy patients
develop physical dependence[4]
0
FDA-approved treatments for
opioid-induced physical dependence (OIPD)
or Neonatal Opioid Withdrawal Syndrome (NOWS)
The Physical Dependence Problem
Physical dependence develops in the majority of patients on long-term opioid therapy and is distinct from addiction. In these patients, physical dependence manifests as an ‘interdose withdrawal’, with symptoms such as anxiety, restlessness, pain sensitization, and dysphoria that emerge between doses. These symptoms drive dose escalation, compulsive use patterns, and, ultimately, inability to taper or discontinue opioids even when medically appropriate. No approved pharmacotherapy exists to address this core mechanism.
Why Existing Approaches Fall Short
Current opioid antagonists (naltrexone, naloxone) act as inverse agonists in the opioid-dependent state, precipitating acute withdrawal and blocking analgesia, making them unsuitable for patients actively receiving opioid therapy. Partial agonists (buprenorphine) typically require opioid abstinence and withdrawal prior to induction, carry their own dependence liability, and are not indicated for treating opioid-induced physical dependence in pain patients.[5] ATX-1209 is the only known compound designed to treat physical dependence while patients remain on opioid therapy — addressing the problem at its molecular root.[6]
Sources
[1] CDC. About Overdose Prevention, 2026.
[2] National Center for Health Statistics. Provisional Drug Overdose Death Counts (12 months ending December 2025), 2026.
[3] NIH Pathways to Prevention Workshop. The Role of Opioids in the Treatment of Chronic Pain, 2014.
[4] Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349:1943–53.
[5] Sadee W, Oberdick J, Wang Z. Biased opioid antagonists as modulators of opioid dependence. Molecules 2020;25:4163.
[6] Sadee W, McKew JC. Ligand-free signaling of GPCRs: relevance to µ opioid receptors. Molecules 2022;27:5826.
Our Science

A New Class of Opioid Modulation

ATX-1209 (oral 6β-naltrexol) represents a mechanistically distinct approach to opioid-induced physical dependence — not an agonist, not a classical antagonist.

⚙

Neutral µ-Opioid Receptor Modulator

ATX-1209 occupies the µ-opioid receptor without suppressing its basal (constitutive) signaling. Inverse agonists such as naltrexone and naloxone suppress that signaling in the opioid-dependent state, precipitating withdrawal and blocking analgesia. At low doses, ATX-1209 is designed to gradually return the constitutively active MOR-µ* state to the resting MOR-µ state, with a substantially lower propensity to precipitate withdrawal.

Sadee & McKew, Molecules 2022 · Sadee et al., Molecules 2020

◎

Preserves Analgesia

In preclinical models, 6β-naltrexol prevented opioid dependence at doses roughly 35- to 70-fold below those that block opioid antinociception, and single intravenous doses up to 20 mg did not antagonize morphine analgesia in healthy volunteers. ATX-1209 is designed to reduce dependence while patients continue to receive pain relief from their opioid therapy; this has not yet been tested in patients on chronic opioid therapy.

Sirohi et al., J Pharmacol Exp Ther 2009 · Safa et al., Front Pharmacol 2021 · Yancey-Wrona et al., Pain Med 2011

Mechanism of Action — MOR-µ* Reconversion

Dependence and analgesia are separable at the level of the receptor. Chronic opioid exposure is proposed to drive the µ-opioid receptor into a sustained, ligand-free, constitutively active state (MOR-µ*) that perpetuates dependence independently of the agonist. ATX-1209 is designed to gradually return MOR-µ* to the resting MOR-µ state — a process termed retrograde addiction modulation — while analgesia from the opioid agonist is preserved.

With chronic opioid therapy, the agonist-bound receptor produces analgesia, while repeat dosing shifts MOR into a constitutively active state (MOR-μ*) proposed to drive dependence.

ATX-1209 mechanism of action schematic Top: an opioid agonist bound to the mu-opioid receptor produces analgesia and opioid-induced constipation. Bottom: repeat opioid dosing shifts the resting receptor MOR-mu into a constitutively active, ligand-free state MOR-mu-star that is proposed to drive physical dependence, interdose withdrawal, and hyperalgesia. With ATX-1209, a neutral mu-opioid receptor modulator, MOR-mu-star is designed to gradually return to the resting state while agonist analgesia is preserved. Mechanistic hypothesis. Acute agonist effects Opioid agonistAgonist-bound MOR Analgesia preserved Opioid-induced constipation* ATX-1209 Receptor adaptation with repeat dosing Resting MOR-μLigand-free signaling: low Repeat opioiddosing Active MOR-μ* (pro-dependent)MOR-μ* → MOR-μLigand-free signaling: elevatedSignaling returns toward basal ATX-1209 Constitutive signaling drives dependence Gradual return to resting state Dependence-related effects Physical dependence Interdose withdrawal Hyperalgesia

Mechanistic schematic (hypothesis). Constitutive, ligand-free MOR-μ* activity is proposed to drive opioid dependence; ATX-1209 (6β-naltrexol), a neutral μ-opioid receptor modulator, is designed to gradually restore the resting state while agonist analgesia is preserved. Sources: Sadée & McKew, Molecules 2022; Corder et al., Science 2013.

*Supported by exploratory human IV 6β-naltrexol data; benefit with oral ATX-1209 remains to be established. Yancey-Wrona et al., Pain Med 2011.

Pipeline

Multi-Indication Development Strategy

A single molecule with therapeutic potential across the continuum of opioid-induced harm — from chronic pain dependence to neonatal withdrawal.

Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
Opioid-Induced Physical Dependence in Chronic Opioid Pain Therapy
Phase 1 (Planned)

ATX-1209 is a first-in-class, oral, neutral μ-opioid receptor modulator designed to reduce opioid-induced physical dependence in patients on chronic opioid pain therapy while preserving analgesia. A Phase 1a single ascending dose study in healthy volunteers is planned, followed by a Phase 1b/2a proof-of-concept study.
Opioid Use Disorder (OUD)
Preclinical

Opioid use disorder is a follow-on indication. By targeting the constitutively active MOR-µ* state proposed to drive dependence, ATX-1209 could complement existing OUD treatments; stand-alone and opioid co-formulation approaches are under consideration.
Neonatal Opioid Withdrawal Syndrome (NOWS)
Preclinical (In Progress)

A high-urgency unmet need in infants exposed to opioids in utero. In a pregnant guinea pig model, low-dose 6β-naltrexol co-administered with methadone prevented neonatal withdrawal signs. Safety in pregnancy has not yet been established.
Combat & Acute Pain (Opioid Co-formulation)
Discovery (Exploratory)

Co-formulation of ATX-1209 with standard opioid analgesics (e.g., fentanyl, morphine) for acute and field use, designed to preserve immediate pain relief while limiting the receptor changes proposed to drive dependence.
Cancer Pain Adjunct
Discovery (Exploratory)

Adjunctive therapy for cancer patients requiring high-dose, long-term opioid analgesia, aimed at reducing the physical dependence and interdose withdrawal that accompany sustained opioid therapy.
Lead Indication
Follow-on
Exploratory
In Progress / Next Stage Planned
Leadership

World-Class Drug Development Expertise

Our team combines decades of experience in opioid pharmacology, CNS drug development, regulatory strategy, and clinical operations.

Senior Management
Aaron Schuchart
Aaron Schuchart
President & Chief Executive Officer
Bio
Aaron Schuchart is a multifaceted leader with more than 30 years of operational, financial management, and business development experience, along with extensive industry relationships. He has spent most of his career structuring and negotiating biopharma transactions, raising capital, and forming new ventures. Prior to Aether Therapeutics, he served as Chief Business Officer at two publicly traded biotechnology companies focused on rare diseases and cancer. Previously, he was part of the early management team at Coherus Biosciences, which advanced a protein engineering platform from startup to a late-stage publicly traded company. He previously held senior business development roles at Amgen and Novartis and served as Managing Director of ProAltus Partners, a boutique advisory firm providing commercial strategy and deal support to early-stage companies. He holds a BBA in Accounting from Texas Tech University and an MBA in Finance from the UCLA Anderson School of Management.
LinkedIn
Wolfgang Sadee, PhD
Wolfgang Sadee, PhD
Chief Scientific Officer & Founder
Bio
A globally recognized authority in opioid pharmacology and personalized medicine. Professor Emeritus at Ohio State University College of Medicine and UCSF. Over 400 publications spanning opioid pharmacology and pharmacogenomics. Recognized by ScholarGPS (2025) in the top 0.05% of scholars worldwide. Originating scientist behind the MOR-µ* constitutive activity model and ATX-1209.
LinkedIn
Bruce Imbert, MD, PhD, MPH
Bruce Imbert, MD, PhD, MPH
Chief Medical Officer & Head of R&D
Bio
Bruce has more than 20 years of clinical development, regulatory and strategy at Indivior, Tempero Bio and Pear Therapeutics. He is a proven leader in developing CNS therapies, including significant accomplishments in the areas of pain and addiction. He most recently led the development programs for Sublocade, a buprenorphine formulation approved for the treatment of OUD, and Opvee, an opioid antagonist for use in opioid overdose. He holds patents in substance use disorder therapeutics, served on the NIH/NIDA Medication Development Research Study Section, and earned his MD, PhD, and MPH from Aix-Marseille University, followed by postdoctoral training in clinical pharmacology.
LinkedIn
Laurence Nore, MBA
Laurence Nore, MBA
Fractional Chief Operating Officer
Bio
Over 25 years of operational, financial, and business development experience in biopharmaceuticals including Amgen, PDL Biopharma, and Roche Diagnostics. Most recently at IgGenix, established the Australian subsidiary and managed the CRO and clinical sites for their First-in-Human trial.
LinkedIn
Board of Directors
Rick Hawkins
Rick Hawkins
Founder & Chairman
Bio
40-year veteran in biotechnology and pioneer in the CRO/CDMO industries. Founded multiple companies with notable exits including Pharmaco/PPD and Sensus/Pfizer. Most recently Founder, President & CEO of Lumos Pharma. Current board member of Savara and Plus Therapeutics; advisor to the President’s Innovation Council at UT Austin.
LinkedIn
Jon Saxe
Jon Saxe
Board Member & Lead Director
Bio
Extensive governance experience across 25+ boards with multiple successful exits. Former VP of Corporate Development & Licensing at Hoffmann-La Roche, CEO of Synergen, and President of PDL Biopharma (1995–2000). Currently Lead Director of Kyto Technology and Life Sciences.
LinkedIn
Phil Skolnick, PhD, DSc
Phil Skolnick, PhD, DSc (hon.)
Board Member
Bio
Phil Skolnick has served in both the public and private sectors. Following a 25-year career at the NIH Intramural Research Program, he was appointed a Lilly Fellow in Neuroscience. Three years later, he and his colleagues founded DOV Pharmaceuticals, a NASDAQ listed corporation. At DOV, he served as Chief Scientific Officer and later as President and CSO. He rejoined the NIH in 2010 as Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse. He returned to the private sector in 2017 as Chief Scientific Officer at Opiant Pharmaceuticals, which was listed on NASDAQ in 2018. Opiant was acquired by Indivior in March 2023. Skolnick served as a Fellow at Indivior from 2023–2025.
LinkedIn
John D. Harris
John D. Harris
Board Member
Bio
As a member of Aether Therapeutics’ Board of Directors, John Harris brings a strong background in clinical trials, and leadership experience at large, medium and start-up organizations in the biotech and cell therapy fields. He currently is the CEO of BioFire Defense and previously served as Aether’s President & CEO between June 2022 and January 2025. John’s deep operational, executive and market development capabilities are assets to the board.
LinkedIn
John McKew, PhD
John McKew, PhD
Board Member
Bio
John McKew is President and Chief Scientific Officer of Lumos Pharma. Dr. McKew has twenty-seven years of experience developing novel therapeutics where he successfully advanced therapies through preclinical and into clinical development. Prior to Lumos Pharma, Dr. McKew served as V.P. of research at aTyr Pharma where he led a research team discovering and advancing protein-based therapeutics for rare diseases. He has also served as Acting Scientific Director for the National Center for Advancing Translational Science (NCATS) intramural group, a part of the National Institutes of Health (NIH).
LinkedIn
Advisors
Bob Davis
Bob Davis
Senior Advisor, Clinical & Regulatory
Bio
Bob Davis has over 35 years of experience in biopharma and global CROs designing, advising and conducting clinical trials at Lumos, Parke Davis, Searle, Sensus, Pharmaco among others. He has also been part of the development of multiple drugs that received FDA approval.
LinkedIn
Investors

Why Aether Therapeutics

Aether Therapeutics is advancing a differentiated, first-in-class therapeutic platform to address the molecular cause of opioid-induced physical dependence — a significant unmet medical need affecting millions of patients worldwide.

◆
Novel Mechanism
ATX-1209 is the only known neutral µ-opioid receptor modulator in development for opioid-induced physical dependence — a mechanistically distinct approach that targets the constitutively active MOR-µ* state proposed to drive dependence.
▣
Significant Unmet Need
No approved therapy exists for preventing or mitigating physical dependence in patients maintained on opioids to treat chronic pain. Neonatal Opioid Withdrawal Syndrome (NOWS) similarly lacks a targeted pharmacotherapy. ATX-1209 is designed as an oral adjunct to reduce dependence while preserving analgesia.

Safa et al., Front Pharmacol 2021

2025 Annual Report (Form C-AR)
Key Publications

Scientific Foundation

The scientific basis for ATX-1209 is grounded in two decades of peer-reviewed research on µ-opioid receptor constitutive activity, opioid pharmacology, and 6β-naltrexol pharmacodynamics.

2023
Ligand-free signaling of G-protein-coupled receptors: physiology, pharmacology, and genetics
Sadee W, McKew JC
Molecules · Expanded GPCR Signaling Framework
View on PubMed →
2022
Ligand-free signaling of G-protein-coupled receptors: relevance to µ opioid receptors in analgesia and addiction
Sadee W, McKew JC
Molecules · MOR-µ* Constitutive Activity & ATX-1209 Model
View on PubMed →
2021
Pharmacological prevention of neonatal opioid withdrawal in a pregnant guinea pig model
Safa A, Lau AR, Aten S, Schilling K, Bales KL, Miller VA, Fitzgerald J, Chen M, Hill K, Dzwigalski K, Obrietan K, Phelps MA, Sadee W, Oberdick J
Frontiers in Pharmacology · NOWS Preclinical Data
View on PubMed →
2020
Biased opioid antagonists as modulators of opioid dependence: opportunities to improve pain therapy and opioid use management
Sadee W, Oberdick J, Wang Z
Molecules · Biased Antagonist & 6β-Naltrexol Framework
View on PubMed →
2016
Preferential delivery of an opioid antagonist to the fetal brain in pregnant mice
Oberdick J, Ling Y, Phelps MA, Yudovich MS, Schilling K, Sadee W
J Pharmacol Exp Ther. · Fetal Brain Selective Antagonist Delivery
View on PubMed →
2011
6β-Naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: An exploratory study
Yancey-Wrona J, Dallaire B, Bilsky E, Bath B, Burkart J, Webster L, Magiera D, Yang X, Phelps M, Sadee W
Pain Med. · Peripheral Selectivity & GI Motility Study
View on PubMed →
2009
The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity
Sirohi S, Dighe SV, Madia PA, Yoburn BC
J Pharmacol Exp Ther. · Neutral Antagonist vs. Inverse Agonist Potency
View on PubMed →
2005
In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice
Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadée W, Bilsky EJ
J Pharmacol Exp Ther. · 6β-Naltrexol In Vivo Characterization
View on PubMed →
News & Press Releases

Latest Updates

June 16, 2026
Aether Therapeutics Selected to Present at the Prestigious Venture Summit West
Aether Therapeutics selected as one of youngStartup Ventures' Top Innovators to present its pipeline to VCs and corporate investors at Mountain View, CA.
March 18, 2026
Aether Therapeutics Strengthens Leadership with Three Key Appointments
Dr. Bruce Imbert and Laurence Nore join the senior management team as CMO & Head of R&D and Fractional COO, respectively. Dr. Phil Skolnick appointed to the Board of Directors.
December 2025
CSO Wolfgang Sadee Honored as Highly Ranked Scholar by ScholarGPS
Dr. Sadee recognized in the top 0.05% of scholars worldwide in personalized medicine and related disciplines in the 2025 Global Scholar Rankings by ScholarGPS.
Contact

Get in Touch

Aether Therapeutics is headquartered in Austin, Texas. For investor inquiries, partnership opportunities, or general information, please reach out.

General Inquiries
info@aetherthx.com
LinkedIn
Aether Therapeutics
About Aether Therapeutics

Aether Therapeutics is a clinical-stage biotech company targeting the molecular cause of dependence to bring patients safe and effective therapies for pain and opioid use disorders.

Austin, Texas

June 16, 2026

Aether Therapeutics Selected to Present at the Prestigious Venture Summit West

Company chosen by youngStartup Ventures to present its groundbreaking addiction modulator pipeline to top-tier VCs and corporate investors

Austin, TX — June 16, 2026 — Aether Therapeutics, a pioneer in addiction modulator therapeutics, today announced its selection to present at the 2026 Venture Summit West, taking place June 16–17, 2026 at the Computer History Museum in Mountain View, California. Hosted by youngStartup Ventures, the summit is recognized as one of the nation's premier forums where bold ideas meet the capital and connections needed to fuel tomorrow's breakthroughs.

The Venture Summit West will spotlight 200 Top Innovators across sectors that are redefining the way we live, work, and thrive. Handpicked by the youngStartup Ventures selection committee, these presenting companies represent the cutting edge of innovation—from life-changing biotech and AI-driven platforms to transformative clean energy and frontier technologies.

By earning a coveted spot on this stage, Aether Therapeutics will showcase its groundbreaking pipeline to a powerhouse audience of venture capitalists, corporate investors, angel networks, and industry visionaries eager to discover the next category-defining companies.

“Being selected for the Venture Summit West is a fantastic honor. We're excited to share our vision, connect with global investors, and accelerate the impact of our work in transforming the treatment of pain and addiction.”
— Aaron Schuchart, CEO of Aether Therapeutics

Celebrated for its unmatched networking opportunities, the Venture Summit West has become a must-attend gathering for those shaping the future of entrepreneurship. Beyond the presentations, attendees will experience venture panels, intimate roundtables, and high-impact networking sessions designed to foster meaningful connections and investment opportunities.

About Venture Summit West

Hosted by youngStartup Ventures, the Venture Summit West convenes the brightest entrepreneurs, investors, and thought leaders driving innovation forward. Over two dynamic days, attendees explore the trends, technologies, and partnerships defining the future economy. For more information on the Venture Summit West, visit youngstartup.com/upcoming.

About Aether Therapeutics

Aether Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for pain and addiction. With a commitment to addressing one of the most urgent public health crises of our time, Aether Therapeutics is advancing its lead compound, ATX-1209, designed to provide opioid-equivalent analgesia without the risk of dependence.

Media & Investor Contact

Laurence Nore, COO & Head of Investor Relations
Email: info@aetherthx.com

March 18, 2026

Aether Therapeutics Strengthens Leadership with Three Key Appointments

Company welcomes Dr. Bruce Imbert and Laurence Nore to the Senior Management Team and appoints renowned neuroscientist Dr. Phil Skolnick to the Board of Directors

Austin, TX — March 18, 2026 — Aether Therapeutics (“Aether”), a clinical-stage biopharmaceutical company dedicated to addressing opioid addiction and advancing non-addictive treatments for pain, today announced three significant leadership appointments: Dr. Bruce Imbert and Ms. Laurence Nore have joined the senior management team as Chief Medical Officer & Head of R&D and Fractional Chief Operating Officer, respectively. Additionally, Dr. Phil Skolnick has joined the company’s Board of Directors. Together, these appointments bring world-class scientific, clinical, and operational expertise to Aether as it advances its lead candidate, ATX-1209.

Bruce Imbert, MD, PhD, MPH, and Laurence Nore, MBA Strengthen Aether’s Management Team

Aether Therapeutics has appointed Bruce Imbert, MD, PhD, MPH, as Chief Medical Officer and Head of Research & Development and Laurence Nore, MBA, as Fractional Chief Operating Officer. Dr. Imbert is a globally experienced CNS drug developer and proven operational leader with deep expertise spanning addiction medicine, psychiatry and digital therapeutics. Appointed to the NIH/NIDA Medication Development Research Study Section, he brings a career encompassing the full development lifecycle – from preclinical strategy through regulatory approval and post-marketing execution – across multiple international markets. Most recently, he led the post-approval program at Indivior for a long-acting injectable buprenorphine formulation approved for the treatment of opioid use disorder, and an intranasal opioid antagonist indicated for opioid overdose reversal. His regulatory and clinical development track record in the addiction space makes him uniquely positioned to advance ATX-1209 from IND submission through global clinical development and regulatory approval.

Ms. Nore brings over 25 years of experience in senior operational, financial, and business development roles across the biopharmaceutical industry, and is recognized as a strategic and tactical leader in R&D project management, deal-making, and financings. Most recently, at IgGenix, she established and managed the company’s Australian entity and oversaw execution of the Phase 1 clinical program.

Phil Skolnick, Ph.D., D.Sc. (hon.), Joins Board of Directors

Aether Therapeutics is pleased to announce the appointment of Dr. Phil Skolnick to its Board of Directors. A renowned neuropharmacologist, Dr. Skolnick brings extraordinary drug development, regulatory, and business experience across pain, addiction, and neuropsychiatric medicine. He previously led the Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse (NIDA), where he oversaw a broad portfolio of CNS research and clinical development programs. Most recently, Dr. Skolnick served as Chief Scientific Officer of Opiant Pharmaceuticals, where he led the development of multiple programs for substance use disorders prior to the company’s acquisition by Indivior. He also served on the Board of Directors of Gilgamesh Pharmaceuticals, a neuropsychiatric biotech company that was recently acquired by AbbVie for up to $1.2 billion.

“Aether is pursuing a scientifically compelling and clinically urgent mission. The pharmacology underlying ATX-1209 represents a truly differentiated approach to chronic pain and opioid use disorder — one that I believe has significant potential to change how these conditions are treated. I am honored to join the Board and look forward to contributing to the company’s continued progress.”
— Phil Skolnick, PhD
“I am thrilled to welcome Bruce, Laurence, and Phil to the Aether Therapeutics family. Bruce brings extensive hands-on expertise in getting OUD therapies across the finish line with the FDA, and Laurence’s operational acumen, deal-making experience, and track record in running lean, effective clinical programs is central to our execution. Phil’s career is a testament to what is possible when rigorous science is paired with real-world drug development discipline — his experience at NIDA, Opiant, and Gilgamesh brings critical strategic and scientific capital that will help us achieve our mission. Together, these three leaders reflect our ambition and our confidence in ATX-1209’s potential to make a real difference for patients.”
— Aaron Schuchart, President & CEO

About Aether Therapeutics

Aether Therapeutics is a clinical-stage biopharmaceutical company seeking to address the global opioid crisis by targeting the molecular cause of dependence. The company’s lead candidate, ATX-1209, is a novel addiction modulator designed to mitigate opioid dependence and reverse the upregulated basal MOR signaling that drives addiction — while preserving analgesic efficacy and without inducing withdrawal or abuse liability. ATX-1209’s differentiated mechanism offers potential clinical utility across opioid use disorder, non-addictive pain therapy in combination with opioid agonists, and prevention and treatment of neonatal opioid withdrawal syndrome. Aether’s scientific foundation is built on the pioneering research of founder and Chief Scientific Officer Dr. Wolfgang Sadee, a globally recognized authority in opioid pharmacology and personalized medicine.

Contact: info@aetherthx.com
December 2025

CSO & Founder Wolfgang Sadee Honored as a Highly Ranked Scholar by ScholarGPS

Recognition Underscores Company’s Commitment to Excellence in Novel Pain and Addiction Therapeutics

Austin, Texas — December 2025 — Aether Therapeutics, a clinical-stage biopharmaceutical company developing safer therapeutics for pain and addiction, today announced that Dr. Wolfgang Sadee, CSO, has been honored as a Highly Ranked Scholar by ScholarGPS in the 2025 Global Scholar Rankings, placing him in the top 0.05% of scholars worldwide in personalized medicine and related disciplines.

This prestigious recognition reflects Dr. Sadee’s exceptional career trajectory, prolific publication record, and outstanding contributions to biomedical innovation — areas that directly align with Aether Therapeutics’ mission to transform pain management and addiction treatment through precision therapeutics.

“We are proud to see Wolfgang Sadee’s world-class expertise recognized on such a distinguished platform. His leadership in opioid research and personalized medicine has been instrumental in advancing our scientific strategy and bringing breakthrough solutions to patients who desperately need safer alternatives.”
— Aaron Schuchart, President & CEO

ScholarGPS rankings are determined by artificial intelligence and data science analysis of over 200 million publications and 3 billion citations, evaluating scholars across 30 million researchers and 120,000 institutions globally. The Highly Ranked Scholar designation honors exceptional lifetime achievement and recent contributions across specific scientific and clinical disciplines.

Privacy Policy

Last Updated: May 27, 2026

Aether Therapeutics (“Aether,” “we,” “our,” or “us”) is committed to protecting your privacy. This Privacy Policy describes how we collect, use, store, and disclose your information when you visit our website at www.aethertherapeutics.com. Aether Therapeutics is a clinical-stage biopharmaceutical company developing ATX-1209, a first-in-class oral μ-opioid receptor modulator targeting the molecular cause of opioid-induced physical dependence.

Please read this Privacy Policy carefully to understand our policies and practices regarding your information. If you do not agree with our policies, you should not access or use the Site.

1. Information We Collect

When you access and browse our Site, we collect certain limited categories of information automatically and through voluntary communications. The Site is primarily informational in nature.

A. Information Collected Automatically

We use standard server logs and analytical tracking technologies (such as cookies) to collect details about your device and interactions. This information includes:

  • Internet Protocol (IP) addresses.
  • Browser type, version, and language settings.
  • Operating system and device model.
  • Referral pages, landing pages, and search queries that led you to the Site.
  • Usage data (e.g., page views, timestamp, clicks, and duration of visit).

B. Information You Voluntarily Provide

If you contact us directly via email (e.g., sending inquiries to info@aetherthx.com), we collect your name, email address, company name (if applicable), and any other information you choose to include in your message.

2. How We Use Your Information

We use the information we collect for the following business purposes:

  • To operate, maintain, and optimize the performance and responsiveness of our Site.
  • To monitor Site security, detect fraud, and prevent unauthorized access or system abuse.
  • To respond to your inquiries, investor requests, or partnership questions.
  • To analyze traffic patterns and compile aggregate statistics on Site usage.

3. CCPA / CPRA Compliance (California Resident Rights)

Under the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (collectively “CCPA/CPRA”), California residents have specific rights regarding their personal information. Because we collect minimal, aggregate browsing information, Aether Therapeutics adheres to the following frameworks:

No Sale or Sharing of Personal Information

Aether Therapeutics does not sell your personal information, and we do not share it with third parties for cross-context behavioral advertising. We have not sold or shared any personal information in the preceding 12 months.

Your California Rights:

  • Right to Know / Access: You have the right to request that we disclose the categories of personal information we have collected about you, the categories of sources, the business purpose, and the specific pieces of personal information collected.
  • Right to Delete: You have the right to request that we delete the personal information we have collected from you, subject to certain legal exceptions (such as maintaining security or complying with regulatory obligations).
  • Right to Correct: You have the right to request that we correct inaccurate personal information that we maintain about you.
  • Right to Non-Discrimination: We will not discriminate against you (e.g., denying service or providing a lower level of quality) for exercising any of your CCPA/CPRA rights.

To exercise any of these rights, please contact us at info@aetherthx.com.

4. CIPA Compliance (California Information Privacy Act)

We are committed to complying with the California Information Privacy Act (“CIPA”) best practices regarding data collection and tracking:

  • We do not utilize session replay software or keylogging scripts that record your active keystrokes, form fills, or mouse movements.
  • Any analytics trackers implemented on our Site are configured solely to measure aggregated, non-identified web traffic for statistical performance. We do not transmit individual user data or browsing histories to third parties for commercial use.
  • Your browser settings can be configured to block cookies. If you reject cookies, you may still access the Site, though some limited layout features might function differently.

5. Children's Privacy

Our Site is not intended for, nor directed at, individuals under the age of 16. We do not knowingly collect, solicit, or maintain personal information from children. If we learn that we have collected personal information from a child under the age of 16 without parental consent, we will delete that information as quickly as possible. If you believe we might have collected information from a child under 16, please contact us at info@aetherthx.com.

6. Data Security and Retention

We implement appropriate technical and organizational measures designed to secure your personal information from accidental loss and unauthorized access. However, please remember that no method of transmission over the Internet or electronic storage is 100% secure.

We retain the minimal server traffic data we collect only for as long as necessary to fulfill the operational security and analysis purposes described in this policy, or to comply with applicable legal and audit requirements.

7. Contact Information

If you have any questions, comments, or concerns about this Privacy Policy or our data practices, please contact us at:

Aether Therapeutics
Email: info@aetherthx.com
Location: Austin, Texas